Study of LGX818 and Cetuximab or LGX818, BYL719, and Cetuximab in BRAF Mutant Metastatic Colorectal Cancer

Back to Search
Print
Bookmark Trial

NCT01719380

Last updated date
Back to Search
Print
Bookmark Trial
FOR MORE INFORMATION
Study Location
USC/Kenneth Norris Comprehensive Cancer Center USC 2
Los Angeles, California, 90033, United States
See other locations
Contact
1-800-718-1021
[email protected]
Related Links

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Colorectal Cancer
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18 + years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Metastatic colorectal cancer

- Progression after at least one prior standard of care regimen or be intolerant to irinotecan-based regimens

- Life expectancy ≥ 3 months

- ECOG performance status ≤ 2

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


- Symptomatic or untreated leptomeningeal disease


- Symptomatic brain metastasis


- Patients with clinically manifested diabetes


- Acute or chronic pancreatitis


- Clinically significant cardiac disease


Other protocol-defined inclusion/exclusion criteria may apply.

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

Call Now

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Advanced Search

Based on your search, you may also be interested in

Colorectal CancerDacomitinib Plus PD-0325901 in Advanced KRAS Mutant NSCLC
NCT02039336
  1. Amsterdam,
  2. Rotterdam,
  3. Utrecht,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Colorectal CancerStudy of LGX818 and Cetuximab or LGX818, BYL719, and Cetuximab in BRAF Mutant Metastatic Colorectal Cancer
NCT01719380
  1. Los Angeles, California
  2. Los Angeles, California
  3. New Haven, Connecticut
  4. Boston, Massachusetts
  5. Hackensack, New Jersey
  6. New York, New York
  7. Columbus, Ohio
  8. Nashville, Tennessee
  9. Nashville, Tennessee
  10. Salt Lake City, Utah
  11. Parkville, Victoria
  12. Leuven,
  13. Toronto, Ontario
  14. Montreal, Quebec
  15. Montpellier Cedex 5,
  16. Toulouse Cedex 9,
  17. Essen,
  18. Köln,
  19. Modena, MO
  20. Kashiwa, Chiba
  21. Chuo-ku, Tokyo
  22. Seoul, Korea
  23. Seoul, Korea
  24. Utrecht, The Netherlands
  25. Amsterdam,
  26. Rotterdam,
  27. Oslo,
  28. Sevilla, Andalucia
  29. Barcelona, Catalunya
  30. Madrid,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Colorectal CancerFluorouracil and Leucovorin With or Without Irinotecan in Treating Patients Following Surgery for Stage III Colorectal Cancer
NCT00026273
  1. Vienna (Wien),
  2. Leuven,
  3. Cairo,
  4. Paris,
  5. Paris,
  6. Hamburg,
  7. Bergamo,
  8. Firenze (Florence),
  9. Milano (Milan),
  10. Terni,
  11. Udine,
  12. Porto,
  13. Cordoba,
  14. Geneva,
  15. Sutton, England
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Colorectal CancerLeucovorin and Fluorouracil With or Without SU5416 in Treating Patients With Metastatic Colorectal Cancer
NCT00004252
  1. Montgomery, Alabama
  2. Arcadia, California
  3. La Jolla, California
  4. Los Angeles, California
  5. Los Angeles, California
  6. San Francisco, California
  7. Boca Raton, Florida
  8. Tampa, Florida
  9. Honolulu, Hawaii
  10. Baton Rouge, Louisiana
  11. Baltimore, Maryland
  12. Boston, Massachusetts
  13. East Lansing, Michigan
  14. Minneapolis, Minnesota
  15. Fort Lee, New Jersey
  16. Hackensack, New Jersey
  17. Valhalla, New York
  18. Charlotte, North Carolina
  19. Raleigh, North Carolina
  20. Scranton, Pennsylvania
  21. Chattanooga, Tennessee
  22. Nashville, Tennessee
  23. Dallas, Texas
  24. Galveston, Texas
  25. Houston, Texas
  26. Madison, Wisconsin
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE Study of LGX818 and Cetuximab or LGX818, BYL719, and Cetuximab in BRAF Mutant Metastatic Colorectal Cancer
Official Title  ICMJE A Phase lb/II Multi-center, Open-label, Dose Escalation Study of LGX818 and Cetuximab or LGX818, BYL719, and Cetuximab in Patients With BRAF Mutant Metastatic Colorectal Cancer
Brief Summary This study will assess the safety and efficacy of LGX818 when combined with cetuximab or combined with cetuximab and BYL719 in patients with BRAF mutant metastatic colorectal cancer
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 1
Phase 2
Study Design  ICMJE Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Colorectal Cancer
Intervention  ICMJE
  • Drug: LGX818
  • Drug: Cetuximab
  • Drug: BYL719
Study Arms  ICMJE
  • Experimental: LGX818 + cetuximab
    Interventions:
    • Drug: LGX818
    • Drug: Cetuximab
  • Experimental: LGX818 + BYL719 + cetuximab
    Interventions:
    • Drug: LGX818
    • Drug: Cetuximab
    • Drug: BYL719
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: April 16, 2019)		156
Original Estimated Enrollment  ICMJE
 (submitted: October 30, 2012)		124
Actual Study Completion Date  ICMJE February 12, 2019
Actual Primary Completion Date October 31, 2015   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Metastatic colorectal cancer
  • Progression after at least one prior standard of care regimen or be intolerant to irinotecan-based regimens
  • Life expectancy ? 3 months
  • ECOG performance status ? 2

Exclusion Criteria:

  • Symptomatic or untreated leptomeningeal disease
  • Symptomatic brain metastasis
  • Patients with clinically manifested diabetes
  • Acute or chronic pancreatitis
  • Clinically significant cardiac disease

Other protocol-defined inclusion/exclusion criteria may apply.

Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Australia,   Belgium,   Canada,   France,   Germany,   Italy,   Japan,   Korea, Republic of,   Netherlands,   Norway,   Spain,   United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT01719380
Other Study ID Numbers  ICMJE CLGX818X2103
2012-002138-35 ( EudraCT Number )
C4221002 ( Other Identifier: Pfizer )
Has Data Monitoring Committee Not Provided
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE
Plan to Share IPD:Yes
Plan Description:Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/d….
URL:https://www.pfizer.com/science/clinical_trials/trial_data_and_results/d…
Responsible Party Pfizer
Study Sponsor  ICMJE Pfizer
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director:Pfizer CT.gov Call CenterPfizer
PRS Account Pfizer
Verification Date July 2020

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP